molnupiravir - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.10 [0.01, 0.92]< 10%2 studies (2/-)97.9 %some concernnot evaluable moderatecrucial-
deaths 0.10 [0.01, 0.92]< 10%2 studies (2/-)97.9 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.48 [0.30, 0.78]< 10%1 study (1/-)99.9 %lownot evaluable highcrucial-
hospitalization 0.49 [0.30, 0.79]< 10%1 study (1/-)99.8 %lownot evaluable highimportant-
viral clearance 14.50 [1.70, 123.69]> 10%1 study (1/-)99.2 %some concernnot evaluable moderateimportant-
viral clearance by day 7 14.50 [1.70, 123.69]> 10%1 study (1/-)99.2 %some concernnot evaluable moderateimportant-

safety endpoints 00

AE leading to drug discontinuation 0.51 [0.25, 1.07]< 10%2 studies (2/-)96.3 %some concernnot evaluable moderateimportant-
serious adverse events 0.71 [0.49, 1.04]< 10%2 studies (2/-)95.9 %some concernnot evaluable moderateimportant-
adverse events 0.90 [0.73, 1.12]< 10%2 studies (2/-)82.2 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.